Tilray® Announces Support of Two New Clinical Research Studies in Australia and Canada
Tilray CBD and THC capsules will be used in a study examining the
safety, tolerability and effectiveness of medical cannabis on immune
activation in people living with HIV being conducted by the
Tilray’s support of numerous studies conducted by leading research institutions and hospitals around the world reflects the need for more clinical data in the medical cannabis field and the Company’s commitment to advancing cannabinoid-based science to further understand the benefits it can offer to critical patient populations
“Tilray is at the forefront of clinical research in the medical cannabis
field and we’re very proud to support two groundbreaking studies that
have potential to identify more indications in which medical cannabis
can benefit patients in-need,” says
Over 50,000 youth in
“We are committed to increasing the scientific understanding of
cannabinoid-based medicine as treatment for pediatric patients with
intellectual disability and associated severe behavioral problems
through this study.” says Associate Professor
The single site, double-blind, parallel group, randomized, placebo-controlled pilot study of 10 participants, compares CBD with a placebo in reducing Severe Behavioral Problems in pediatric patients aged eight to 16 years of age with Intellectual Disability. Participants are randomized 1:1 to receive either Tilray C100 oral solution or the placebo.
The results from this trial are expected to be published by 2020.
Despite antiretroviral therapy (ART), persistent immune activation is associated with increased risk of non-opportunistic complications in people living with HIV, such as cardiovascular, pulmonary, renal and hepatic events. Research has suggested that medical cannabis may hold many potential therapeutic benefits for PLWH due to its promising anti-inflammatory and anti-fibrotic effects.
The use of medical cannabis to potentially benefit people living with
HIV has been largely unexplored due to regulatory restrictions which
impeded its thorough evaluation in the past decade. The changing
regulatory environment and access to high-quality pharmaceutical-grade
cannabis products has allowed researchers to begin generating critical
data in support of this patient population, living with a number of
difficult-to-treat conditions. The trial led by
“There is a critical need for more data on methods to reduce chronic
immune activation in People Living with HIV,” says Dr.
The randomized open-label interventional study will measure the safety,
tolerability and effectiveness of
The trial is expected to begin in the second half of 2019. More information about the trial will be shared in the coming months.
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
“forward-looking information” within the meaning of Canadian securities
laws, or collectively, forward-looking statements. Forward-looking
statements in this press release may be identified by the use of words
such as, “may”, “would”, “could”, “will”, “likely”, “expect”,
“anticipate”, “believe, “intend”, “plan”, “forecast”, “project”,
“estimate”, “outlook” and other similar expressions, including
statements in respect to Tilray’s medical cannabis products.
Forward-looking statements are not a guarantee of future performance and
are based upon a number of estimates and assumptions of management in
light of management’s experience and perception of trends, current
conditions and expected developments, as well as other factors that
management believes to be relevant and reasonable in the circumstances,
including assumptions in respect of current and future market
conditions, the current and future regulatory environment and future
approvals and permits. Actual results, performance or achievement could
differ materially from that expressed in, or implied by, any
forward-looking statements in this press release, and, accordingly, you
should not place undue reliance on any such forward-looking statements
and they are not guarantees of future results. Please see the heading
“Risk Factors” in Tilray’s Annual Report on Form 10-K, which was filed
Source: Tilray, Inc.
For further information:
Media: Chrissy Roebuck, +1-833-206-8161, email@example.com
Investors: Katie Turner, +1-646-277-1228, Katie.firstname.lastname@example.org
Patients in Australia and New Zealand: 1800-361-664, email@example.com
Patients in Canada: 1-844-845-7291,firstname.lastname@example.org